Fang B - Search Results

1

Dominant Negative RAS as an anticancer agent.

Guo W, Fang B. Guo W, et al. Among authors: fang b. Cancer Biol Ther. 2006 Nov;5(11):1492-3. doi: 10.4161/cbt.5.11.3681. Epub 2006 Nov 11. Cancer Biol Ther. 2006. PMID: 17204860 Free article. No abstract available.

2

Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer.

Bouvet M, Ellis LM, Nishizaki M, Fujiwara T, Liu W, Bucana CD, Fang B, Lee JJ, Roth JA. Bouvet M, et al. Among authors: fang b. Cancer Res. 1998 Jun 1;58(11):2288-92. Cancer Res. 1998. PMID: 9622060

3

Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression.

Ji L, Fang B, Yen N, Fong K, Minna JD, Roth JA. Ji L, et al. Among authors: fang b. Cancer Res. 1999 Jul 15;59(14):3333-9. Cancer Res. 1999. PMID: 10416589

4

Adenoviral Bak overexpression mediates caspase-dependent tumor killing.

Pataer A, Fang B, Yu R, Kagawa S, Hunt KK, McDonnell TJ, Roth JA, Swisher SG. Pataer A, et al. Among authors: fang b. Cancer Res. 2000 Feb 15;60(4):788-92. Cancer Res. 2000. PMID: 10706081

5

Antitumor effect of adenovirus-mediated Bax gene transfer on p53-sensitive and p53-resistant cancer lines.

Kagawa S, Gu J, Swisher SG, Ji L, Roth JA, Lai D, Stephens LC, Fang B. Kagawa S, et al. Among authors: fang b. Cancer Res. 2000 Mar 1;60(5):1157-61. Cancer Res. 2000. PMID: 10728665

6

Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53).

Yen N, Ioannides CG, Xu K, Swisher SG, Lawrence DD, Kemp BL, El-Naggar AK, Cristiano RJ, Fang B, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Merritt JA, Mukhopadhyay T, Nesbitt JC, Nguyen D, Perez-Soler R, Pisters KM, Putnam JB Jr, Schrump DS, Shin DM, Walsh GL, Roth JA. Yen N, et al. Among authors: fang b. Cancer Gene Ther. 2000 Apr;7(4):530-6. doi: 10.1038/sj.cgt.7700138. Cancer Gene Ther. 2000. PMID: 10811470 Clinical Trial.

7

Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers.

Gu J, Kagawa S, Takakura M, Kyo S, Inoue M, Roth JA, Fang B. Gu J, et al. Among authors: fang b. Cancer Res. 2000 Oct 1;60(19):5359-64. Cancer Res. 2000. PMID: 11034071

8

Significant augmentation of pro-apoptotic gene therapy by pharmacologic bcl-xl down-regulation in mesothelioma.

Mohiuddin I, Cao X, Fang B, Nishizaki M, Smythe WR. Mohiuddin I, et al. Among authors: fang b. Cancer Gene Ther. 2001 Aug;8(8):547-54. doi: 10.1038/sj.cgt.7700332. Cancer Gene Ther. 2001. PMID: 11571532

9

hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity.

Gu J, Andreeff M, Roth JA, Fang B. Gu J, et al. Among authors: fang b. Gene Ther. 2002 Jan;9(1):30-7. doi: 10.1038/sj.gt.3301619. Gene Ther. 2002. PMID: 11850720

10

Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo.

Ji L, Nishizaki M, Gao B, Burbee D, Kondo M, Kamibayashi C, Xu K, Yen N, Atkinson EN, Fang B, Lerman MI, Roth JA, Minna JD. Ji L, et al. Among authors: fang b. Cancer Res. 2002 May 1;62(9):2715-20. Cancer Res. 2002. PMID: 11980673 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,474 results

Search Page

Filters